Dika Ojiakor, PhD
Dika joined Drug Discovery News as a Junior Science Editor in 2025. He earned his PhD from Western University in 2024 and continued his scientific training there as a Postdoctoral Fellow. His doctoral and postdoctoral research focused on elucidating early neurobiological changes in Alzheimer's disease. As a graduate student, Dika served as Editor-in-Chief of The Dorsal Column. Outside of work, he enjoys trail running and reading historical non-fiction.
Articles by Dika Ojiakor, PhD
| 10 min read
Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.
| 5 min read
Explore how the immune system battles mold in lungs. A new study reveals a key cytokine, GM-CSF, helps immune cells clear the dangerous fungal spores.
| 4 min read
The therapy lengthened telomeres and improved immune function in people with telomere biology disorder, showing promise for treating bone marrow failure safely.
| 6 min read
QurAlis researchers have developed QRL-101, a new drug candidate that targets overactive neurons to prevent cell death in ALS.
| 4 min read
Biotech and pharma leaders reveal the neurological therapies in development that they’re most excited about.
| 4 min read
In a Phase 2b trial, Khondrion’s sonlicromanol led to significant health benefits for patients with mitochondrial disease linked to a common mutation.
| 10+ min read
The 2025 Breakthrough Prize in Life Sciences honors discoveries in GLP-1 drugs, multiple sclerosis, and DNA editing that transform human health.
| 5 min read
Michelle Werner and her team at Alltrna are developing novel tRNA therapeutics to overwrite mutations shared by hundreds of rare genetic diseases.
| 4 min read
Targeting a gut bacterial species or its metabolites could potentially improve diabetes management by reducing sugar preferences.
| 4 min read
Xaira Therapeutics is leveraging novel generative AI models to design medicines for diseases without treatments.
Page 1 of 1 - 10 Total Items
